Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders

Jaguar Health, Inc. (NASDAQ:JAGX) announced the approval of all five proposals at its Annual Meeting of Stockholders held on June 21, 2024. Details of the proposals can be found in the company's definitive proxy statement filed with the SEC.

Jaguar is set to disclose the results of its pivotal phase 3 OnTarget trial for crofelemer, a cancer supportive care drug, by July 23, 2024. An investor webcast will present these updates, featuring Jaguar's scientific team, patient advocates, and leading oncology experts.

In honor of World Rainforest Day, Jaguar shared a podcast interview with ethnobotanist Dr. Steven King, highlighting the medicinal uses of rainforest plants and their impact on global health. The interview is available on RealPharma's podcast series.